Clinical Progress and Outlook ... attributable to higher expense associated with clinical trials and one-time employee termination benefits primarily offset by lower preclinical research expense ...

Sensei is conducting a multi-center Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of solnerstotug as both a monotherapy and in ...

Named Ron Weitzman, M.D., F.A.C.P., as part-time Chief Medical Officer. Cash Position: Cash, cash equivalents and marketable securities were $41.3 million as of December 31, 2024, as compared to $ ...

While inflation remains above the Fed’s 2% target, core consumer prices have decelerated significantly over the past year, signaling progress in ... 17% during the same time to reach $31.7 ...

The Keytruda combination improved both overall survival and progression-free survival – the time it took for patients' cancer to progress ... with their drug Libtayo (cemiplimab), and ...

Analysts at JPMorgan anticipate a recovery in biotech funding at the same time, pointing to indications ... driven by important products like EYLEA, Libtayo, and Dupixent. With over a million ...

While inflation remains above the Fed’s 2% target, core consumer prices have decelerated significantly over the past year, signaling progress in ... Dupixent, Libtayo, Kevzara, and others.

At the quantum level, the past and the future are indiscernible. That could have profound effects on the world we can see.